| B6 | More frequent viral load testing, with point-of-care tests has no impact on viral suppression in postpartum HIV-positive women in a randomized controlled trial in 2 clinics in Johannesburg, South Africa | Oral abstract session with live Q&A | Viral load and CD4 measurement |
| B63 | Obsession with suppression: comparison of virally suppressed and unsuppressed children and adolescents living with HIV (CALHIV) treated with dolutegravir regimens in Mbeya and Mwanza, Tanzania | Oral abstract session with live Q&A | Adherence in paediatric and adolescent populations |
| B7 | A rapid enzymatic assay for selective detection of HIV drugs that indicate long-term and short-term PrEP adherence | Oral abstract session with live Q&A | ART adherence measurement |
| C32 | Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study | Oral abstract session with live Q&A | Novel delivery systems (e.g., rings, implants, transdermal systems) |
| C21 | High rates of drug resistance in individuals diagnosed with HIV in tenofovir disoproxil fumarate (TDF)-based pre-exposure prophylaxis rollout programs in Kenya, Zimbabwe, Eswatini and South Africa | Oral abstract session with live Q&A | Surveillance of drug resistance in the era of PrEP |
| C27 | Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trial | Oral abstract session with live Q&A | PrEP |
| C27 | Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase | Oral abstract session with live Q&A | PrEP |
| C27 | Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US | Oral abstract session with live Q&A | PrEP |
| C27 | Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW | Oral abstract session with live Q&A | PrEP |
| C57 | No impact of tenofovir/emtricitabine in estradiol exposure among transwomen on oral PrEP: results from the 12-week drug-drug interaction PrEParadas substudy | Oral abstract session with live Q&A | Prevention in transgender populations |